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Aim: To investigate determinants of change in glycated haemoglobin (HbA1c) in patients with
type 2 diabetes mellitus (T2DM) at 6 months after initiating uninterrupted second-line glucose-
lowering therapies.
Materials and Methods: This cohort study utilized retrospective data from 10 256 patients
with T2DM who initiated second-line glucose-lowering therapy (switch from or add-on to met-
formin) between 2011 and 2014 in Germany and the UK. Effects of pre-specified patient char-
acteristics on 6-month HbA1c changes were assessed using analysis of covariance.
Results: Patients had a mean (standard error [SE]) baseline HbA1c of 8.68% (0.02); 28.5% of
patients discontinued metformin and switched to an alternative therapy and the remainder
initiated add-on therapy. Mean (SE) unadjusted 6-month HbA1c change was −1.27% (0.02).
When adjusted for baseline HbA1c, 6-month changes depended markedly on the magnitude of
the baseline HbA1c (HbA1c <9%, −0.45% per unit increase in HbA1c; HbA1c ≥9%, −0.87% per
unit increase in HbA1c). Adjusted mean 6-month HbA1c reductions showed slight treatment
differences (range, 0.92–1.09%; P < .001). Greater reductions in HbA1c were associated with
second-line treatment initiation within 6 months of T2DM diagnosis (1.36% vs 1.03%
[P < .001]) and advanced age (≥70 years, 1.13%; <70 years, 1.02% [P < .001]).
Conclusions: Many patients with T2DM have very high HbA1c levels when initiating second-
line therapy, indicating the need for earlier treatment intensification. Patient-specific factors
merit consideration when making treatment decisions.
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1 | INTRODUCTION
Type 2 diabetes mellitus (T2DM), a chronic and increasingly prevalent
disease, poses a significant clinical and economic burden worldwide.1
The pathophysiology of T2DM is characterized by progressive decline
in β-cell function, with a subsequent reduction in glycaemic control.
Given evidence for a causal link between dysglycaemia and the devel-
opment of microvascular and macrovascular complications, control-
ling blood glucose levels is a major goal of therapy in patients with
T2DM.2–4
Current clinical guidelines recommend the use of metformin
(MET), in conjunction with lifestyle changes, as first-line glucose-
lowering therapy in patients with no contraindications who can
tolerate this therapy.5–8 When MET monotherapy fails to control
glycated haemoglobin (HbA1c), guidelines recommend the addi-
tion of a second glucose-lowering agent such as a sulfonylurea
(SU), a thiazolidinedione, a glucagon-like peptide-1 receptor
antagonist (GLP-1RA), a dipeptidyl peptidase-4 inhibitor (DPP-4i)
or a sodium–glucose linked transporter 2 inhibitor.6,9 A recent
position statement proposed jointly by the American Diabetes
Association (ADA) and the European Association for the Study of
Diabetes (EASD) recommends treatment intensification if glycae-
mic control is not achieved after 3 months of initial therapy.6
In clinical practice, several second- and subsequent-line therapies
are used to treat patients with T2DM, because of a lack of clear con-
sensus on the optimal treatment regimen for the management of
hyperglycaemia, as well as inter-patient differences in the efficacy
and safety profiles of different therapies.6,9 The global DISCOVER
study programme (NCT02322762 and NCT02226822) is designed to
address this knowledge gap.10 DISCOVER comprises 2 prospective
observational studies of patients with T2DM who initiated second-
line glucose-lowering therapy (defined as adding a glucose-lowering
drug or switching between therapies) after failure of first-line oral
treatment (mono-, dual or triple therapy). The studies aim to describe
disease management patterns and treatment outcomes in patients
with T2DM worldwide, and over 16 000 patients in 38 countries
across 6 continents have been enrolled. As part of the DISCOVER
study programme, a retrospective analysis was conducted, using data
from existing electronic medical record (EMR) databases in Canada,
France, Germany and the UK.
This paper reports on an analysis using data from Germany
and the UK. The aims of the present study are: (1) to describe
the changes in HbA1c in patients with T2DM 6 months after
initiating a second-line therapy; and (2) to assess patient charac-
teristics that influence changes in HbA1c after 6 months of
second-line treatment.
2 | METHODS
2.1 | Study design and data source
In this longitudinal cohort study, EMR patient-level data from 2 coun-
tries were extracted from 2 databases: the IMS Disease Analyzer in
Germany compiles drug prescriptions, diagnoses and basic medical
and demographic data from the computer systems of a representative
sample of primary care physicians and internal medicine practices in
Germany11; The Health Improvement Network (THIN) contains
healthcare information from patients registered with participating pri-
mary healthcare practices in the UK.12 Studies have shown THIN to
be representative of the UK population in terms of patient demo-
graphics and the prevalence of major conditions.13,14 No ethical
approval is required for studies based on anonymized databases in
Germany. Studies using THIN have been approved by a nationally
accredited ethics committee12 and specific approval was obtained for
this study from the relevant Scientific Review Committee before
study initiation (reference number: 14THIN052).
2.2 | Study population
Inclusion and exclusion criteria were based on key criteria used in the
prospective DISCOVER studies. Patients (aged ≥18 years) with
T2DM (identified by International Statistical Classification of Diseases
and Related Health Problems, 10th Revision codes or Quality and
Outcomes Framework [QOF] Read codes) (Text S1 of Appendix S1)
who were receiving MET monotherapy as first-line treatment and
initiating a second-line therapy (add-on or switching) were eligible for
inclusion in the study. Patients were required to have a minimum of
12 months of EMR data available before MET initiation, as well as
HbA1c measurements both at second-line treatment initiation and
after 6 months of uninterrupted treatment (defined as no reported
change or cessation of treatment over the 6 months following initia-
tion of second-line therapy). Major exclusion criteria included a diag-
nosis of type 1 diabetes mellitus, use of insulin as first-line treatment,
pregnancy, initiation of a third-line therapy before the 6-month
HbA1c measurement, and treatment with chemotherapy or oral/
intravenous steroids (based on either prescription or relevant diag-
nostic codes within the past 6 months).
Eligible patients were identified from the databases during the
periods May 2011 to April 2014 (Germany) and May 2011 to
November 2013 (UK). The index date was defined as the date of initi-
ation of second-line therapy. Information on demographics and clini-
cal characteristics was recorded using data from the baseline period
before the index date. Variables collected included the type of
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second-line treatment initiated, time since diagnosis of T2DM, time
since first-line treatment initiation, age, body mass index (BMI), sex
and HbA1c. Patients were followed until their 6-month HbA1c meas-
urement, as defined below.
The main outcome of interest was change in HbA1c at 6 months
after initiation of second-line therapy. Data on HbA1c were not
always available for the exact time points of interest (ie, initiation of
second-line therapy and/or after 6 months of follow-up). In such
cases, the HbA1c values used for the analysis were those closest to
the time points of interest, within the following time periods: from
90 days before to 14 days after initiation of second-line therapy for
baseline HbA1c; and from 90 to 270 days after initiation for 6-month
HbA1c. Any HbA1c result <3.5% was considered unrealistically low
and was removed from the data set before patient selection.
2.3 | Statistical analysis
2.3.1 | Baseline characteristics
Baseline variables and clinical characteristics were reported as mean
(standard deviation [SD]) or median (interquartile range [IQR]). The
numbers of patients in different categories for each variable were
reported as number (percentage). Patients were classified according
to the second-line therapy initiated as follows: (1) add-on oral therapy
(either combinations of MET and an SU [MET + SU] or combinations
of MET and a DPP-4i [MET + DPP-4i]); (2) switch to alternative oral
therapy (either SU or DPP-4i monotherapy); (3) switch to or addition
of insulin (insulin monotherapies/combinations of insulin with other
therapies, with or without MET discontinuation); (4) switch to other
monotherapies or combination therapies (including other monothera-
pies, eg, GLP-1RAs, and other combination therapies).
2.3.2 | Assessment of baseline, 6-month change and
baseline-adjusted 6-month change in HbA1c according to
second-line treatment and other variables
Mean HbA1c (standard error) at baseline and 6 months was used to
calculate crude 6-month changes in HbA1c. For each second-line
therapy, the 6-month change in HbA1c was determined using analy-
sis of covariance models adjusted for baseline HbA1c using variance-
weighted least-squares estimation. The relationship between baseline
HbA1c and subsequent 6-month change in HbA1c was explored to
determine the best way to adjust for HbA1c in the analysis. This
included an assessment of linearity, with subsequent exploration of
other types of relationship, including quadratic and spline models (lin-
ear and restricted cubic with differing numbers and locations of
knots), as well as a model using baseline HbA1c as a categorical varia-
ble (full details are provided in Text 2 of Appendix S1).
These linear regression models were also used to assess the
impact of patient characteristics (time since T2DM diagnosis, age,
BMI, sex, country) on 6-month HbA1c changes. Finally, multivariable
analyses adjusted for the aforementioned patient characteristics,
baseline HbA1c and second-line therapies were used to calculate
adjusted estimates of 6-month changes in HbA1c. All statistical ana-
lyses were conducted using STATA 14 software (StataCorp, College
Station, Texas).
3 | RESULTS
3.1 | Patient characteristics
This analysis comprised 10 256 patients with T2DM initiating
second-line glucose-lowering therapy after first-line treatment with
MET in the period 2011 to 2014. Baseline and treatment characteris-
tics are presented in Table 1. The patients were from Germany
(30.4%) and the UK (69.6%). The mean age (SD) of the patients was
62.3 (12.2) years; 85.0% were aged >50 years and 42.3% were
women. Mean (SD) BMI was 32.36 (6.4) kg/m2; 61.0% of patients
were obese (BMI ≥30 kg/m2) and 29.6% were overweight (BMI 25 to
<30 kg/m2). Mean (SD) baseline HbA1c at initiation of second-line
therapy was 8.68% (1.8). Notably, 11.0% of patients had baseline
HbA1c <7.0%. The median (IQR) time between T2DM diagnosis and
second-line treatment initiation was 3.30 (1.29–5.93) years overall,
and 13.8% of patients started second-line treatment during the
6 months following T2DM diagnosis (Table 1). A total of 34.8% of
patients had remained on MET monotherapy for >3 years and 16.4%
had remained on MET monotherapy for ≥5 years.
3.2 | Type 2 diabetes mellitus treatments
For most patients, second-line treatments initiated at baseline com-
prised add-on therapies in combination with MET (MET + SU, 40.9%;
MET + DPP-4i, 30.7%). Another 22.6% of patients switched from
MET to an alternative single agent, the most common agents being
SU (12.5%) and DPP-4i (10.1%). A small proportion of patients
switched to or added insulin therapy to MET (1.7%) or switched to
other monotherapies or combination therapies (4.2%) (Table 1).
Second-line treatment choices differed between countries. Insu-
lin was more commonly chosen in Germany (4.8%) than in the UK
(0.3%) and second-line monotherapies were more common in Ger-
many (46.3%) than in the UK (12.1%). While MET + SU was the most
common second-line treatment choice in the UK (56.8%), it was
rarely chosen in Germany (4.4%), where DPP-4i treatment predomi-
nated (data not shown).
3.3 | Changes in HbA1c at 6 months
The mean (SD) change in HbA1c at 6 months after initiation of
second-line therapy was −1.27% (1.8) (Table 1). The change was
directly, but non-linearly, related to baseline HbA1c (Figure 1). We
explored various statistical modelling options and compared the fit of
each model using measures such as R2; we also conducted adjusted
analyses with each modelling type to compare the results (Text 2 of
Appendix S1). On the basis of our findings, we used linear spline
regression to model the relationship between baseline and 6-month
change in HbA1c as two straight lines connected at a baseline HbA1c
of 9.0%, as this was the simplest reliable model. We conducted sensi-
tivity analyses by reproducing baseline adjusted mean changes in
HbA1c using the various modelling approaches and found agreement
between the estimates from our modelling approach and more com-
plex models (Text 2 of Appendix S1).
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TABLE 1 Characteristics of 10 256 patients with T2DM initiating second-line therapy after first-line treatment with MET
Number of patients (%), by baseline HbA1c category
Characteristic
Overall number of
patients (%) <7%, n = 1129
≥7% and <9%,
n = 5794 ≥9%, n = 3333
Second-line treatment
MET + SU 4191 (40.9) 130 (11.5) 2253 (38.9) 1808 (54.2)
MET + DPP-4i 3147 (30.7) 344 (30.5) 1961 (33.8) 842 (25.3)
SU monotherapy 1278 (12.5) 255 (22.6) 718 (12.4) 305 (9.2)
DPP-4i monotherapy 1031 (10.1) 295 (26.1) 586 (10.1) 150 (4.5)
Insulin (monotherapy or in combination) 178 (1.7) 26 (2.3) 60 (1.0) 92 (2.8)
Other monotherapies or combination
therapies
431 (4.2) 79 (7.0) 216 (3.7) 136 (4.1)
Time between T2DM diagnosis and second-line treatment initiation (index date)
Median (IQR), years 3.30 (1.29–5.93) 3.04 (1.23–5.57) 3.85 (1.08–6.40) 2.40 (0.56–4.98)
Germany 3.37 (1.42–5.72) 3.23 (1.44–5.55) 3.61 (1.65–6.03) 2.85 (0.46–4.93)
UK 3.29 (1.25–5.99) 2.78 (0.82–5.75) 3.95 (1.85–6.48) 2.33 (0.57–5.01)
Proportion of overall cohort in each time
category
<6 months 1313 (13.8) 121 (13.3) 426 (7.9) 766 (24.0)
6 months to <1 year 684 (7.2) 82 (9.0) 362 (6.7) 240 (7.5)
1 to <3 years 2404 (25.3) 244 (26.7) 1363 (25.3) 797 (24.9)
3 to <5 years 1977 (20.8) 188 (20.6) 1189 (22.1) 600 (18.8)
≥5 years 3110 (32.8) 278 (30.4) 2038 (37.9) 794 (24.8)
Missing 768 216 416 136
Time between first- and second-line treatment initiation (index date)
Median (IQR), years 1.96 (0.64–3.93) 1.78 (0.56–3.69) 2.35 (0.96–4.26) 1.39 (0.28–3.20)
Germany 1.90 (0.57–3.88) 1.85 (0.64–3.63) 2.10 (0.75–4.07) 1.39 (0.17–3.34)
UK 2.00 (0.67–3.95) 1.41 (0.41–3.80) 2.43 (1.03–4.36) 1.39 (0.31–3.17)
Proportion of overall cohort in each time
category
<6 months 2229 (21.7) 251 (22.2) 912 (15.7) 1066 (32.0)
6 months to <1 year 1088 (10.6) 156 (13.8) 591 (10.2) 341 (10.2)
1 to <3 years 3369 (32.8) 370 (32.8) 1979 (34.2) 1020 (30.6)
3 to <5 years 1884 (18.4) 175 (15.5) 1197 (20.7) 512 (15.4)
≥5 years 1686 (16.4) 177 (15.7) 1115 (19.2) 394 (11.8)
Age, years
Mean (SD) 62.3 (12.2) 65.93 (11.54) 63.51 (11.58) 59.10 (12.65)
<50 1540 (15.0) 98 (8.7) 698 (12.0) 744 (22.3)
50 to <60 2657 (25.9) 217 (19.2) 1417 (24.5) 1023 (30.7)
60 to <70 2982 (29.1) 340 (30.1) 1785 (30.8) 857 (25.7)
≥70 3077 (30.0) 474 (42.0) 1894 (32.7) 709 (21.3)
Body mass index (kg/m2)
Mean (SD) 32.36 (6.4) 31.07 (6.01) 32.31 (6.21) 32.73 (6.70)
<25 663 (9.4) 80 (14.6) 337 (8.3) 246 (10.0)
25 to <30 2089 (29.6) 174 (31.8) 1246 (30.8) 669 (27.1)
30 to <35 2240 (31.7) 167 (30.5) 1331 (32.9) 762 (30.8)
≥35 2068 (29.3) 127 (23.2) 1147 (28.4) 794 (32.1)
Missing 3196 581 1753 862
Sex
Female 4335 (42.3) 541 (47.9) 3298 (56.9) 2082 (62.5)
Male 5921 (57.7) 588 (52.1) 2496 (43.1) 1251 (37.5)
Country
Germany 3120 (30.4) 831 (73.6) 1711 (29.5) 578 (17.3)
UK 7136 (69.6) 298 (26.4) 4083 (70.5) 2755 (82.7)
(Continues)
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3.4 | Variation in 6-month change in HbA1c
according to choice of second-line treatment
Mean baseline HbA1c varied substantially across treatment groups
(Table 2); values were highest in patients whose second-line treat-
ment was insulin (9.48%) or MET + SU (9.22%), and lowest in those
who switched to DPP-4i monotherapy (7.72%). After 6 months of
second-line treatment, HbA1c decreased in all treatment groups and
there were small differences in the magnitude of this decrease
between groups (Table 2 and Figure S1). The combination of MET +
SU was associated with the largest decrease in HbA1c (1.09%); SU
reduced HbA1c to a greater extent than did DPP-4i, both when used
alone (difference of 0.08%, P = .023) and in combination with MET
(difference of 0.07%, P < .001). Combining MET with SU or DPP-4i
reduced HbA1c more than either monotherapy alone (SU alone: dif-
ference of 0.06%, P = .049; DPP-4i alone: difference of 0.12%,
P < .001; overall difference from monotherapy: 0.09%, P < .001).
Data analysed separately for Germany and the UK are presented in
Tables S1a and S1b (Appendix S1); data showing the proportions of
patients achieving HbA1c <7.0% after 6 months, according to
second-line treatment and baseline HbA1c category, are presented in
Tables S2a and S2b (Appendix S1). Additionally, a sensitivity analysis
TABLE 1 (Continued)
Number of patients (%), by baseline HbA1c category
Characteristic
Overall number of
patients (%) <7%, n = 1129
≥7% and <9%,
n = 5794 ≥9%, n = 3333
Baseline HbA1c (%)
Mean (SD) 8.68 (1.8) – – –
<7.0 1129 (11.0) – – –
7.0 to <8.0 3055 (29.8) – – –
8.0 to <9.0 2739 (26.7) – – –
≥9.0 3333 (32.5) – – –
Absolute reduction in HbA1c at 6 months (%)
Mean (SD) 1.27 (1.8) 0.03 (0.71) 0.69 (0.94) 2.69 (2.19)
No reduction 1857 (18.1) 482 (42.7) 1093 (18.9) 282 (8.5)
<0.5 1818 (17.7) 456 (40.4) 1200 (20.7) 162 (4.9)
0.5 to <1.0 1926 (18.8) 161 (14.3) 1512 (26.1) 253 (7.6)
1.0 to <2.0 2377 (23.2) 30 (2.7) 1663 (28.7) 684 (20.5)
2.0 to <3.0 963 (9.4) 0 306 (5.3) 657 (19.7)
3.0 to <5.0 854 (8.3) 0 20 (0.3) 834 (25.0)
≥5.0 461 (4.5) 0 0 461 (13.8)
Abbreviations: DPP-4i, dipeptidyl peptidase-4 inhibitor; HbA1c, glycated haemoglobin; IQR, interquartile range; MET, metformin; SD, standard deviation;
SU, sulfonylurea; T2DM, type 2 diabetes mellitus.
Data are reported as n (%) unless otherwise stated.
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was conducted in a cohort in which patients with very high baseline
HbA1c (≥12.0%) were excluded. Estimates of 6-month mean HbA1c
change for each second-line treatment group agreed closely with the
overall findings in all patients (Text 2 of Appendix S1).
We next examined whether the relative treatment effects were
dependent on baseline HbA1c by splitting the overall cohort into
patients with baseline HbA1c <9.0% (n = 6923 [67.5%]) and ≥9.0%
(n = 3333 [32.5%]) (Table 2). The results of this subgroup analysis
were generally consistent with findings from the overall cohort. How-
ever, there were several differences; while mean baseline-adjusted
HbA1c reduction was smallest with DPP-4i monotherapy in the main
analysis, this was not the case in the subgroup of patients with
HbA1c ≥9.0%. It is important to note that the number of patients
with HbA1c ≥9.0% who received DPP-4i monotherapy was small
(n = 150 vs 881 in the <9.0% group).
In patients with baseline HbA1c ≥9.0%, the mean baseline-
adjusted reduction in HbA1c was slightly greater in patients who
initiated insulin as second-line treatment (3.05%), compared with the
other treatment groups (P = .036 vs all other treatment groups com-
bined). However, the number of patients in this insulin-treated sub-
group was small (n = 86).
3.5 | Determinants of change in HbA1c following
initiation of second-line glucose-lowering therapies
3.5.1 | Country
There was weak evidence that the median (IQR) time between initia-
tion of first- and second-line treatments differed between countries,
with a shorter time to treatment intensification in Germany than in
the UK (1.90 [0.57–3.88] vs 2.00 [0.67–3.95] years; P = .075). When
adjusted for baseline HbA1c, the 6-month changes in HbA1c were
slightly greater in Germany than in the UK (−1.11% vs −1.04%;
P = .001; Table 3).
3.5.2 | Time between diagnosis of type 2 diabetes
mellitus and initiation of second-line therapy
Mean HbA1c at baseline was higher in patients starting second-line
treatment during the 6 months following diagnosis (9.88%) than in
those starting treatment beyond this time point (8.70% and 8.55% at
6 months to <1 year and at ≥1 year, respectively; Table 3). The mean
baseline-adjusted 6-month change in HbA1c was significantly greater
in patients who initiated treatment during the 6 months following
T2DM diagnosis, than in those who initiated treatment ≥6 months
after T2DM diagnosis (−1.36% vs −1.03%; P < .001).
3.5.3 | Age
Patients who switched to another monotherapy as second-line treat-
ment tended to be older than those receiving second-line combination
therapies (mean age of patients initiating non-MET monotherapy
[SU or DPP-4i] vs MET combination therapy [MET + SU or MET +
DPP-4i], 66.79 years vs 61.06 years). The mean age of patients receiv-
ing an SU was 62.99 years, compared with 61.69 years in those taking
a DPP-4i, a difference of 1.3 years (P < .001). The mean baseline-
adjusted change in HbA1c was lower in patients aged <70 years
(−1.02%) than in patients aged ≥70 years (−1.13%; P < .001) (Table 3).
3.5.4 | Body mass index
Mean BMI was highest in patients initiating MET + DPP-4i and lowest in
patients initiating insulin (33.8 kg/m2 vs 29.7 kg/m2; P < .001). While
there was little association between baseline HbA1c and BMI (Table 3),
there was an inverse association between mean baseline-adjusted
6-month change in HbA1c and BMI (<35 kg/m2, −1.09%; ≥35 kg/m2,
−0.94%; P < .001).
3.5.5 | Sex
In patients receiving an SU or DPP-4i as monotherapy or in combina-
tion with MET, women were more likely than men to switch to another
TABLE 2 Changes in HbA1c by second-line treatment
Second-line
treatment
Baseline
HbA1c, %
6-month
change in
HbA1c, %
Baseline-adjusted 6-
month change in
HbA1c, %a
Mean (SE) baseline-adjusted
6-month change in HbA1c
(%), for the subgroup with
baseline HbA1c <9.0%b
(n = 6923)
Mean (SE) baseline-adjusted
6-month change in HbA1c
(%), for the subgroup with
baseline HbA1c ≥9.0%c
(n = 3333)
MET + SU 9.22 (0.03) −1.68 (0.03) −1.09 (0.02) −0.65 (0.02) −2.74 (0.04)
MET + DPP-4i 8.42 (0.03) −1.04 (0.03) −1.02 (0.02) −0.58 (0.02) −2.56 (0.05)
SU monotherapy 8.27 (0.05) −1.00 (0.05) −1.00 (0.03) −0.55 (0.03) −2.70 (0.09)
DPP-4i monotherapy 7.72 (0.05) −0.59 (0.05) −0.92 (0.03) −0.47 (0.03) −2.78 (0.12)
Insulin (monotherapy
or in combination)
9.48 (0.13) −2.11 (0.13) −1.00 (0.08) −0.45 (0.09) −3.05 (0.17)
Other monotherapies
or combination
therapies
8.48 (0.08) −1.11 (0.08) −1.05 (0.05) −0.61 (0.05) −2.65 (0.13)
Overall 8.68 (0.02) −1.27 (0.02) −1.05 (0.02) −0.58 (0.01) −2.70 (0.03)
Abbreviations: DPP-4i, dipeptidyl peptidase-4 inhibitor; HbA1c, glycated haemoglobin; MET, metformin; SE, standard error; SU, sulfonylurea.
Data are reported as mean (SE).
a For patients with mean baseline HbA1c (8.68%), estimated from a linear regression model with slope −0.45% (0.01) per unit increase in HbA1c for base-
line HbA1c <9.0% and −0.86% (0.02) per unit increase in HbA1c for baseline HbA1c ≥9.0%.
b Estimates for patients with mean baseline HbA1c 7.69% for the subgroup <9.0% HbA1c at baseline. Slope is −0.45% (0.01) per unit increase in HbA1c.
c Estimates for patients with mean baseline HbA1c 10.75% for the subgroup ≥9.0% HbA1c at baseline. Slope is −0.87% (0.02) per unit increase in
HbA1c.
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monotherapy (SU or DPP-4i; 52.5% vs 47.5%; P < .001), rather than
adding either drug to MET. Mean baseline HbA1c and mean baseline-
adjusted 6-month change in HbA1c were slightly higher in men than in
women (mean baseline HbA1c, 8.80% vs 8.52% [P < .001]; 6-month
HbA1c change, −1.10% vs −0.98% [P < .01]; Table 3).
3.6 | Multivariable regression analysis
When simultaneously modelling the effects of all previously examined
variables on 6-month change in HbA1c, we found that the following
were significantly associated with greater baseline-adjusted 6-month
reductions in HbA1c: residence in Germany (vs the UK); <6 months
between T2DM diagnosis and second-line treatment initiation; older
age; lower BMI and male sex (vs female) (Table 4). HbA1c reductions
were higher with MET + SU compared with other second-line treat-
ment options, but the differences between groups were small. Thus,
overall, the findings from this multivariate regression analysis were
consistent with the results of univariate anaysis.
4 | DISCUSSION
4.1 | Overview of study findings
The aim of this study was to elucidate determinants of change in
HbA1c following initiation of second-line glucose-lowering therapies,
using data from 2 nationally representative databases. After
6 months of second-line treatment, overall mean baseline-adjusted
HbA1c levels decreased by approximately 1.1%, regardless of the
second-line therapy. The 6-month change in HbA1c was influenced
by several patient characteristics: baseline HbA1c, country, time since
T2DM diagnosis, age, BMI and sex.
4.2 | Treatment patterns in patients initiating
second-line therapy
A key finding from this study was that most (89%) patients had
inadequate glycaemic control (baseline HbA1c ≥7.0%) and almost
one-third of patients had baseline HbA1c ≥9.0%. This is suggestive
of a delay in treatment intensification, as has been reported in sev-
eral real-world studies in the UK and elsewhere.15–17 Major guide-
lines stipulate the need for treatment intensification if patients
receiving MET monotherapy do not achieve HbA1c targets within
3 months; however, in a recent retrospective cohort analysis of
>80 000 patients with T2DM in the UK, Khunti et al. reported
delays in treatment intensification of >7 years, which resulted in
prolonged periods of poor glycaemic control. These findings are sig-
nificant, given the substantial body of evidence of a beneficial effect
of timely establishment of glycaemic control on HbA1c reductions
and diabetes complications.6,18,19 Moreover, there is evidence of a
sustained legacy effect of early intensive glucose control; in a 10-
year follow-up of the UK Prospective Diabetes Study, patients who
TABLE 3 Other potential influences on 6-month change in HbA1c
Number of patients Baseline HbA1c, %
Baseline-adjusted
change in HbA1c, %a
Country
Germany 3120 7.91 (0.03) −1.11 (0.02)
UK 7136 9.02 (0.02) −1.04 (0.02)
Time between T2DM diagnosis and second-line treatment initiation
<6 months 1313 9.88 (0.05) −1.36 (0.03)
6 months to <1 year 684 8.70 (0.07) −0.97 (0.04)
≥1 year 7491 8.55 (0.02) −1.02 (0.02)
Missing 768 7.84 (0.06) −1.08 (0.03)
Age (years)
<50 1540 9.24 (0.05) −0.82 (0.03)
50 to <60 2657 8.89 (0.03) −1.04 (0.02)
60 to <70 2982 8.59 (0.03) −1.11 (0.02)
≥70 3077 8.31 (0.03) −1.13 (0.02)
Body mass index (kg/m2)
<25 663 8.99 (0.07) −1.19 (0.04)
25 to <30 2089 8.77 (0.04) −1.11 (0.02)
30 to <35 2240 8.79 (0.04) −1.04 (0.02)
≥35 2068 8.88 (0.04) −0.94 (0.02)
Missing 3196 8.35 (0.03) −1.09 (0.02)
Sex
Female 4335 8.52 (0.03) −0.98 (0.02)
Male 5921 8.80 (0.02) −1.10 (0.02)
Abbreviations: HbA1c, glycated haemoglobin; SE, standard error; T2DM, type 2 diabetes mellitus.
Data are reported as mean (SE).
a For patients with mean baseline HbA1c (8.68%).
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received early intensive glucose-lowering therapy experienced a
continued reduction in microvascular risks, as well as emergent risk
reductions for cardiovascular events, compared with patients who
received conventional therapy.2
A second important finding was that, despite guideline recom-
mendations to add additional glucose-lowering agents to MET as
second-line therapy, almost 25% of patients in the study cohort
discontinued MET and switched to another monotherapy or insulin
(either as add-on or as a single agent). However, it is important to
acknowledge that an early change in therapy is often attributable
to poor medication tolerability, rather than a lack of glycaemic con-
trol. MET is associated with gastrointestinal side effects in approxi-
mately 25% of patients and is also contraindicated in patients with
renal impairment.20,21 Furthermore, it is noteworthy that the 11%
of patients in the present analysis with HbA1c <7.0% are more
likely than others to have switched therapies because of poor MET
tolerance. Unfortunately, data on patients' reasons for switching
from MET therapy were not documented in the databases used in
this study.
Most patients in the study cohort (71.6%) initiated add-on
therapy with an additional glucose-lowering agent, consistent
with guideline recommendations.5–8 The most commonly pre-
scribed add-on therapies were SUs and DPP-4is. Interestingly,
while MET + SU was the most popular choice of second-line
treatment in the UK (56.8%), it was rarely chosen in Germany
(4.4%). This may be because, until 2015, the UK National Institute
for Health and Care Excellence guidelines recommended SUs as
the add-on therapy of choice when intensifying treatment in
patients with T2DM.22 Moreover, while a treatment algorithm
proposed by the German Diabetes Society presents MET + SU
and MET + DPP-4i as equivalent treatment options,23 MET +
DPP-4i may have recently replaced MET + SU in Germany,
because of the lower risk of weight gain and hypoglycaemia with
DPP-4i than with SU therapy.6,9,24,25
TABLE 4 Results from a multivariable regression analysis for 6-month change in HbA1c
Number of patients
Mean adjusted difference (95% CI) in 6-month
change in HbA1c (%) compared with reference
groupa P value
Country
Germany 3120 −0.17 (−0.22, −0.12) <.001
UK 7136 – –
Second-line treatment
MET + SU 4191 – –
MET + DPP-4i 3147 0.09 (0.04, 0.14) <.001
SU monotherapy 1278 0.18 (0.12, 0.24) <.001
DPP-4i monotherapy 1031 0.28 (0.21, 0.35) <.001
Insulin (monotherapy or in combination) 178 0.24 (0.08, 0.40) .003
Other monotherapies or combination therapies 431 0.11 (0.01, 0.20) .027
Time since diagnosis to second-line treatment initiation (years)
<0.5 1313 −0.39 (−0.45, −0.32) <.001
0.5 to <1 684 0.01 (−0.06, 0.09) .768
≥1 7491 – –
Unknown 768 −0.01 (−0.07, 0.06) .856
Age (years)
<50 1540 0.34 (0.27, 0.40) <.001
50 to <60 2657 0.12 (0.06, 0.17) <.001
60 to <70 2982 0.03 (−0.01, 0.08) .167
≥70 3077 – –
Body mass index (kg/m2)
<25 663 −0.16 (−0.25, −0.07) <.001
25 to <30 2089 −0.10 (−0.16, −0.03) .002
30 to <35 2240 −0.04 (−0.10, 0.02) .182
≥35 2068 – –
Unknown 3196 −0.06 (−0.12, 0.00) .036
Sex
Female 4335 0.12 (0.08, 0.15) <.001
Male 5921 – –
Abbreviations: CI, confidence interval; DPP-4i, dipeptidyl peptidase-4 inhibitor; HbA1c, glycated haemoglobin; MET, metformin; SU, sulfonylurea.
Data are reported as mean (95% CI).
a Estimates are from a multivariable regression model, adjusted for baseline HbA1c and all other variables in the table, for those with mean baseline
HbA1c (8.68%).
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4.3 | Changes in 6-month HbA1c with second-line
diabetes treatments
After 6 months of second-line treatment, HbA1c decreased in all
treatment groups and there was a non-linear relationship between
baseline HbA1c and 6-month HbA1c change. There were some small
differences between treatment groups, with combination therapies
associated with larger HbA1c reductions than monotherapies, and
SUs associated with slightly greater HbA1c reductions than DPP-4is.
However, these findings should be considered carefully, given that
this was a descriptive study and, therefore, not designed to test
hypotheses or to formally compare the effectiveness of treatments.
Therefore, it is our view that the choice of second-line treatment had
only a modest impact on 6-month baseline-adjusted HbA1c reduc-
tions, even after controlling for covariates in a multivariable analysis.
Moreover, these findings were broadly consistent across all baseline
HbA1c values. These real-world findings were consistent with a
recent meta-analysis, in which all investigated drug classes lowered
HbA1c to a similar extent when combined with MET,26 as well as
with findings from a primary care database study in Germany.27
Given the similar efficacy of all second-line treatments, their associ-
ated side effects (eg, risks of weight gain, hypoglycaemia) and addi-
tional benefits (eg, weight reduction, blood pressure reduction)6,9
may be the most important considerations when selecting second-
line treatment options for patients with T2DM.
4.4 | Additional determinants of change in HbA1c
following initiation of second-line glucose-lowering
therapies
As seen previously, there was a positive relationship between baseline
HbA1c and the magnitude of 6-month HbA1c reductions.28 Our multi-
variable analysis revealed 5 additional patient characteristics that
affected baseline-adjusted 6-month HbA1c reductions following initia-
tion of second-line glucose-lowering therapy. These included country,
age and sex, as well as the “modifiable” variables: time since T2DM diag-
nosis and BMI. While the magnitude of the effects of country, BMI and
sex were small and, therefore, probably insignificant from a clinical per-
spective, it is worth noting that small differences may have a cumulative
effect when considered from a public health perspective. For example,
the proportion of patients achieving HbA1c <7.0% after 6 months of
continuous second-line treatment was higher in Germany than in the UK
(46.9% vs 34.7%), an effect probably attributable to the lower mean
baseline HbA1c and the slightly higher baseline-adjusted reduction in
HbA1c in Germany compared with that in the UK (baseline HbA1c:
7.91% vs 9.02%; baseline-adjusted HbA1c reduction: 1.11% vs 1.04%).
Thus, it may be pertinent for clinicians to consider additional patient
characteristics, particularly age and time since T2DM diagnosis, when
making treatment decisions, in accordance with recommendations from
a recent joint statement from the ADA and the EASD.6
4.5 | Study strengths and limitations
Particular strengths of this study were the use of large representative
cohorts, the use of data from 2 countries and the ability to adjust
6-month HbA1c changes for baseline HbA1c values. Furthermore,
the use of multivariable analysis enabled the effects of individual
patient characteristics on 6-month HbA1c changes to be assessed in
isolation.
Limitations of the present study include the fact that patient
medical records show prescriptions rather than medication use, so
analyses assume patient adherence to study medication.29,30 Addi-
tionally, the reasons for changing treatment or initiating a particular
second-line therapy are not routinely captured in EMRs. Patients
who switch therapy might be more likely to do so as a consequence
of adverse events than of poor glycaemic control; the opposite may
be true of patients who initiate add-on therapy to MET. EMR studies
depend on recording of patient data by phycisians, which presents
the possibility of some information being omitted; however, the fre-
quency of this is expected to be low.
In this analysis, HbA1c data were not always available for the
exact time points of interest, an issue that necessitated the use of
time windows, and which may have impacted the precision of the
analysis. There was also inconsistency in the accuracy and complete-
ness of the variables of interest, and no data were included on pre-
scription of diet or exercise or on the socio-economic status of
patients. Furthermore, the present analysis does not include data
from patients taking sodium–glucose linked transporter 2 inhibitors,
an important new class of glucose-lowering drugs, because these
medicines were not approved by the European Medicines Agency at
the start of the study. There are also no data on GLP-1RAs.
4.6 | Conclusions
Key findings from this study were, first, that second-line glucose-
lowering therapies are frequently initiated far later and at higher
HbA1c levels than those recommended by guidelines. Second, almost
one-quarter of patients in the study discontinued MET therapy,
which is more than expected if guideline recommendations were
applied. While the 6-month change in HbA1c did not differ much
according to choice of second-line therapy, there was a non-linear
relationship between baseline HbA1c and 6-month HbA1c changes.
Moreover, certain additional patient characteristics, including time
since T2DM diagnosis and age, merit consideration when making
treatment decisions. These data will complement future results from
the prospective DISCOVER studies.
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